In 2019, The Crews group developed an MDM2/nutlin‐based BRD4 degrader A1874 with potent degradation on BRD4 protein and inhibition on the growth of cancer cells harboring a wild type p53 (Table 1 and Figure 4; MDM2‐2).350. The gene discussed is TP53; the disease is cancer.